A multimorbid patient with heart failure and long-term treatment with enhanced external counterpulsation: a case report

Management of multimorbid patients is challenging, despite advances in pharmacotherapy and widespread use of surgical treatment. The combination of diseases such as coronary artery disease leading to heart failure, hypertension, type 2 diabetes and chronic kidney disease requires an individualized approach to the patient. Adjuvant non-invasive therapies could facilitate the management of such patients. In addition, the use of longer-term non-pharmacological treatment is associated with prolonged follow-up by medical personnel, which can improve patient adherence to therapy and, thus, their quality of life.

This article presents a case of long-term follow-up and complex management of a patient with multimorbid pathology, including heart failure of ischemic etiology, with the addition of enhanced external counterpulsation in intermittent mode to therapy.

1. Mamieva ZA, Lishuta AS, Belenkov YuN, et al. Possibilities of Enhanced External Counterpulsation Using in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2017;13(2):238-47. (In Russ.) doi:10.20996/1819-6446-2017-13-2-238-247.

2. Bockeria LA, Bockeria OL, Glushko LA, et al. New opportunities, pro­spects and the expansion of clinical indications for the use of enhanced external counterpulsation. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2021;22(2):119-29. (In Russ.) doi:10.24022/1810-0694-2021-22-2-119-129.

3. Xu L, Cui M, Zhao W. The Effect of EECP on Ischemic Heart Failure: a Systematic Review. Curr Cardiol Rep. 2023;25(10): 1291-8. doi:10.1007/s11886-023-01943-1.

4. Akhtar M, Wu G, Du Z, et al. Effect of External Counterpulsation on Plasma Nitric Oxide and Endothelin-1 Levels. Am J Cardiol. 2006;98(1):28-30. doi:10.1016/j.amjcard.2006.01.053.

5. Luo C, Liu D, Wu G, et al. Effect of enhanced external counter­pulsation on coronary slow flow and its relation with endothelial function and inflammation: a mid-term follow-up study. Cardio­logy. 2012;122(4):260-8. doi:10.1159/000339876.

6. Wang Q, Hao J, Jiang W, et al. Enhanced external counter­pulsation increases coronary flow reserve in coronary microvascular disease. Saudi Med J. 2023;44(12):1277-82. doi:10.15537/smj.2023.44.12.20230427.

7. Hashemi M, Hoseinbalam M, Khazaei M. Long-term effect of enhanced external counterpulsation on endothelial function in the patients with intractable angina. Heart Lung Circ. 2008;17(5):383-7. doi:10.1016/j.hlc.2008.02.001.

8. Efremova EV, Shutov AM, Efremov IM, et al. Using the modified Charlson comorbidity index to predict the risk of death in elderly and senile patients with chronic kidney disease. Nephrologу and Dialуsis. 2022;24(2):349-56. (In Russ.) doi:10.28996/2618-9801-2022-2-349-356.

9. Jan R, Khan A, Zahid S, et al. The Effect of Enhanced External Counterpulsation (EECP) on Quality of life in Patient with Coronary Artery Disease not Amenable to PCI or CABG. Cureus. 2020;12(5):e7987. doi:10.7759/cureus.7987.

10. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833-40. doi:10.1016/s0735-1097(99)00140-0.

11. Feldman AM, Silver MA, Francis GS, et al. Treating heart failure with enhanced external counterpulsation (EECP): design of the Prospective Evaluation of EECP in Heart Failure (PEECH) trial. J Card Fail. 2005;11(3):240-5. doi:10.1016/j.cardfail.2004.10.001.

12. Soran O, Kennard ED, Kfoury AG, et al. Two-year clinical out­comes after enhanced external counterpulsation (EECP) the­ra­py in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). Am J Cardiol. 2006;97(1):17-20. doi:10.1016/j.amjcard.2005.07.122.

13. Subramanian R, Nayar S, Meyyappan C, et al. Effect of Enhanced External Counter Pulsation Treatment on Aortic Blood Pressure, Arterial Stiffness and Ejection Fraction in Patients with Coronary Artery Disease. J Clin Diagn Res. 2016;10(10):OC30-OC34. doi:10.7860/JCDR/2016/23122.8743.

14. Huang XL, Wang XJ, Chen BT, et al. Clinical efficacy of enhanced external counter pulsation plus sacubitril/valsartan in the treatment of patients with chronic heart failure and the effect on ankle-arm index and cardiac function. Eur Rev Med Pharmacol Sci. 2023;27(8):3300-12. doi:10.26355/eurrev_202304_32101.

15. Wu E, Mårtensson J, Broström A. Enhanced external counter­pulsation in patients with refractory angina pectoris: a pilot study with six months follow-up regarding physical capacity and health-related quality of life. Eur J Cardiovasc Nurs. 2013;12(5):437-45. doi:10.1177/1474515112468067.

16. Sardina PD, Martin JS, Avery JC, et al. Enhanced external counterpulsation (EECP) improves biomarkers of glycemic cont­rol in patients with non-insulin-dependent type II diabetes mellitus for up to 3 months following treatment. Acta Diabetol. 2016; 53(5):745-52. doi:10.1007/s00592-016-0866-9.

17. Dedov I, Shestakova M, Mayorov A, et al. Standards of specialized diabetes care. 11th Edition. Diabetes mellitus. 2023; 26(2S):1-157. (In Russ.) doi:10.14341/DM13042.